Topical Solution for Retinal Delivery: Bevacizumab and Ranibizumab Eye Drops in Anti-Aggregation Formula (AAF) in Rabbits
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Topical Solution for Retinal Delivery: Bevacizumab and Ranibizumab Eye Drops in Anti-Aggregation Formula (AAF) in Rabbits ; volume:41 ; number:6 ; day:5 ; month:6 ; year:2024 ; pages:1247-1256 ; date:6.2024
Pharmaceutical research ; 41, Heft 6 (5.6.2024), 1247-1256, 6.2024
- Urheber
-
Giannos, Steven A.
Kraft, Edward R.
Luisi, Jonathan D.
Schmitz-Brown, Mary E.
Reffatto, Valentina
Merkley, Kevin H.
Gupta, Praveena K.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s11095-024-03721-2
- URN
-
urn:nbn:de:101:1-2409170853047.964565432558
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Giannos, Steven A.
- Kraft, Edward R.
- Luisi, Jonathan D.
- Schmitz-Brown, Mary E.
- Reffatto, Valentina
- Merkley, Kevin H.
- Gupta, Praveena K.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation
Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells
Formulation Stabilization and Disaggregation of Bevacizumab, Ranibizumab and Aflibercept in Dilute Solutions
Topical bromfenac as adjunctive treatment with intravitreal ranibizumab for diabetic macular edema
Funktionelle und morphologische Langzeitergebnisse der Bevacizumab- versus Ranibizumab-Behandlung der retinalen angiomatösen Proliferation
Hydrodynamic Radii of Ranibizumab, Aflibercept and Bevacizumab Measured by Time-Resolved Phosphorescence Anisotropy
Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
Funktionelle und morphologische Langzeitergebnisse der Bevacizumab versus Ranibizumab Behandlung der retinalen angiomatösen Proliferation
Ocular Drug Distribution After Topical Administration: Population Pharmacokinetic Model in Rabbits
Klinische und experimentelle Ergebnisse in der Therapie der altersabhängigen Makuladegeneration mit Ranibizumab und Bevacizumab
Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
Postoperative Complications of True Dropless Cataract Surgery versus Standard Topical Drops
Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation
Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells
Formulation Stabilization and Disaggregation of Bevacizumab, Ranibizumab and Aflibercept in Dilute Solutions
Topical bromfenac as adjunctive treatment with intravitreal ranibizumab for diabetic macular edema
Funktionelle und morphologische Langzeitergebnisse der Bevacizumab- versus Ranibizumab-Behandlung der retinalen angiomatösen Proliferation
Hydrodynamic Radii of Ranibizumab, Aflibercept and Bevacizumab Measured by Time-Resolved Phosphorescence Anisotropy
Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
Funktionelle und morphologische Langzeitergebnisse der Bevacizumab versus Ranibizumab Behandlung der retinalen angiomatösen Proliferation
Ocular Drug Distribution After Topical Administration: Population Pharmacokinetic Model in Rabbits
Klinische und experimentelle Ergebnisse in der Therapie der altersabhängigen Makuladegeneration mit Ranibizumab und Bevacizumab
Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
Postoperative Complications of True Dropless Cataract Surgery versus Standard Topical Drops
Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation
Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells
Formulation Stabilization and Disaggregation of Bevacizumab, Ranibizumab and Aflibercept in Dilute Solutions
Topical bromfenac as adjunctive treatment with intravitreal ranibizumab for diabetic macular edema
Funktionelle und morphologische Langzeitergebnisse der Bevacizumab- versus Ranibizumab-Behandlung der retinalen angiomatösen Proliferation
Hydrodynamic Radii of Ranibizumab, Aflibercept and Bevacizumab Measured by Time-Resolved Phosphorescence Anisotropy
Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
Funktionelle und morphologische Langzeitergebnisse der Bevacizumab versus Ranibizumab Behandlung der retinalen angiomatösen Proliferation
Ocular Drug Distribution After Topical Administration: Population Pharmacokinetic Model in Rabbits
Klinische und experimentelle Ergebnisse in der Therapie der altersabhängigen Makuladegeneration mit Ranibizumab und Bevacizumab
Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD